재조합 수두 대상포진 바이러스 백신

• Main Authors: XU LEITAO, YANG SHUAI, PENG LING, KONG JIAN, JIANG PEI HONG, ZHANG KUN
• Format: Patent
• Language: Korean
• Published: 19.08.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

본 발명은 약독화 생 VZV 균주 (OKA 균주) 유전자의 재조합 당단백질 gE의 세포 외 영역의 아미노산 서열과 인간 면역글로불린의 Fc 세그먼트에 의해 형성된 융합단백질을 포함하는 재조합 수두대상포진 바이러스 백신을 개시하였고, 본 발명은 융합단백질의 제조와 적용, 및 상응하는 재조합 유전자, 진핵 발현 벡터 등을 추가로 포함하며, 본 발명의 융합단백질은 우수한 면역원성을 가지며 높은 수준의 혈청중화 항체생산을 유도할 수 있다. Disclosed in the present invention is a recombinant varicella-zoster virus vaccine, comprising a fusion protein formed by an amino acid sequence of a recombinant glycoprotein gE extracellular region of an attenuated live VZV strain (OKA strain) gene and a human immunoglobulin Fc region. The present invention further comprises preparation for and an application of the fusion protein, and a corresponding recombinant gene, a eukaryotic expression vector, etc. The fusion protein in the present invention has good immunogenicity, and can induce yield of high-level serum neutralizing antibodies.